An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder | Zendy

Carolina L. HaassKoffler | Zendy; Roberta Perciballi | Zendy; Molly Magill | Zendy; Antonella Loche | Zendy; Roberto Cacciaglia | Zendy; Lorenzo Leggio | Zendy; Robert M. Swift | Zendy

Open Access

An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder

Author(s) -

Carolina L. HaassKoffler,

Roberta Perciballi,

Molly Magill,

Antonella Loche,

Roberto Cacciaglia,

Lorenzo Leggio,

Robert M. Swift

Publication year - 2021

Publication title -

psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.378

H-Index - 196

eISSN - 1432-2072

pISSN - 0033-3158

DOI - 10.1007/s00213-021-06008-1

Subject(s) - tolerability , alcohol use disorder , alcohol , pharmacokinetics , psychiatry , psychology , medicine , pharmacology , clinical psychology , adverse effect , biochemistry , chemistry

Previous work suggests that GET 73, a novel compound with putative activity on the metabotropic glutamate receptor subtype 5 (mGluR5), may represent a novel pharmacological treatment for alcohol use disorder (AUD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research